Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus LOCOID LIPOCREAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus LOCOID LIPOCREAM.
CYCLOCORT vs LOCOID LIPOCREAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Locoid Lipocream contains hydrocortisone butyrate, a synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and subsequent synthesis of prostaglandins and leukotrienes. It also suppresses cytokine production, reduces mast cell degranulation, and decreases vascular permeability.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Apply a thin layer to affected area twice daily. Maximum duration of continuous treatment: 4 weeks.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal elimination half-life: ~6-8 hours (hydrocortisone butyrate); clinical context: supports twice-daily dosing
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal: ~1.5% as unchanged hydrocortisone butyrate and metabolites; Biliary/fecal: ~85% as metabolites
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid